| 23687/34351 | US=67 / Biol/Mol Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER |
| 23688/34351 | US=67 / Biol/Mol Wadler S. Molecular targeting in upper gastrointestinal malignancies. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. NEOPLASIAS GASTROINTESTINAIS SUPERIORES; SEGMENTACAO MOLECULAR; CARCINOMA HEPATOCELULAR; CANCER DE PANCREAS; CANCER DE ESTOMAGO; TERAPIA-ALVO |
| 23689/34351 | US=67 / Biol/Mol Sundermeyer ML, Bellacosa A, Meropol NJ. Molecular targeting of colorectal cancer: an idea whose time has come. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 117-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER COLORRETAL; SEGMENTACAO MOLECULAR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR |
| 23690/34351 | US=67 / Biol/Mol Schwartz JD, Llovet JM. Molecular targeting in hepatocellular carcinoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 165-210. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CARCINOMA HEPATOCELULAR; ALVO MOLECULAR; TERAPEUTICA ANTI-ANGIOGENESE; FATORES DE CRESCIMENTO |
| 23691/34351 | US=67 / Biol/Mol Goel A, Kozuch P. Molecularly targeted therapy in pancreatic cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 211-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE PANCREAS; TERAPIA ALVO MOLECULAR; BEVACIZUMABE; CETUXIMABE; ERLOTINIBE; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); TERAPIA ANTI-ANGIOGENICA |
| 23692/34351 | US=67 / Biol/Mol Ho C, Davies AM, Lara PN, Gautschi O, Mach PC, Gumerlock PH, Gandara DR. Untargeted use of targeted therapy: a dilemma in non-small cell lung cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 227-40. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE PULMAO DE CELULAS NAO-PEQUENAS; TERAPIA-ALVO; EGFR; VEGF; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL |
| 23693/34351 | US=67 / Biol/Mol Hahn O, Stadler W. Renal cell carcinoma: renal cell cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 241-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CARCINOMA DE CELULAS RENAIS; CANCER DE CELULAS RENAIS; TERAPIA MOLECULAR |
| 23694/34351 | US=67 / Biol/Mol Heath EI, Carducci MA. Targeted therapies for prostate cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 263-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE PROSTATA; TERAPIA-ALVO; INIBIDORES DA VIA DE SINALIZACAO; INIBIDORES DA ANGIOGENESE; IMUNOTERAPIA; AGENTES ANTI-TUBULINA; AGENTES ANTI-MITOTICOS; AGENTES DE SEGMENTACAO ANTI-VASCULARES |
| 23695/34351 | US=67 / Biol/Mol Azad NS, Sarosy G, Kohn EC. Molecular targets in ovarian cancer and endometrial cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 291-308. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE OVARIO; CANCER ENDOMETRIAL; ALVOS MOLECULARES; TIROSINA-QUINASES; EGFR; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); ONCOGENE; GENES SUPRESSORES DE TUMOR |
| 23696/34351 | US=67 / Biol/Mol Atieh DM, Vahdat LT. Targeted therapy for beast cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 309-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE MAMA; TERAPIA-ALVO; TRASTUZUMABE; HER-2; MICROARRAY; BEVACIZUMABE; VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; LAPATINIBE; ANTICORPOS MONOCLONAIS; INIBIDOR DA TIROSINA QUINASE |
| 23697/34351 | US=67 / Biol/Mol Gupta A, Kirkwood JM. Melanoma. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 343-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MELANOMA; PATOGENESE MOLECULAR; TERAPIA ALVO; INTERFERON; STAT; ANTISENSE BC12; BRAF; APOPTOSE; CICLO CELULAR |
| 23698/34351 | US=67 / Biol/Mol Borghaei H, Binyamin L, Astsaturov I, Weiner LM. Antibody therapy of cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 371-412. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; ANTICORPOS MONOCLONAIS; TERAPIA DE ANTICORPOS; CITOTOXICIDADE CELULAR DEPENDENTE DE ANTICORPO; CITOTOXICIDADE DEPENDENTE DE COMPLEMENTO; IMUNOCONJUGADOS |
| 23699/34351 | US=67 / Biol/Mol Vogl DT, Gewirtz AM. Nucleic acid therapies for cancer treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 413-29. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; ACIDO NUCLEICO; OLIGONUCLEOTIDEOS ANTISENSE; DNA; RNAI |
| 23700/34351 | US=67 / Biol/Mol Nakamura T, Russell SJ. Engineering oncolytic measles viruses for targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 431-45. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. VIRUS ONCOLITICOS; SARAMPO; TERAPIA DE CANCER; TERAPIA-ALVO; VIROTERAPIA |
| 23701/34351 | US=67 / Biol/Mol Perales MA, Wolchok JD, Kaufman HL. Vaccines as targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 447-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 23702/34351 | US=67 / Biol/Mol Koon HB, Atkins MB. Cytokine-based therapy for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 471-507. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; CITOQUINA; INTERFERON; INTERLEUCINA; IMUNOTERAPIA; RESISTENCIA; LEUCEMIA DE CELULAS PILOSAS; LEUCEMIA MIELOIDE CRONICA; LINFOMA NAO-HODGKIN; MELANOMA; CARCINOMA DE CELULAS RENAIS; SARCOMA DE KAPOSI |
| 23703/34351 | US=67 / Biol/Mol Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE |
| 23704/34351 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 23705/34351 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 23706/34351 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |